Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
By
Michael Goodman / Email the Author / “The Pink Sheet” Sep. 12, 2011, Vol. 73, No. 37
Business & Finance / Word Count: 1471 / Article # 00110912021
Executive Summary
Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.